Cherqui Daniel, Laurent Alexis, Tayar Claude, Chang Stephen, Van Nhieu Jeanne Tran, Loriau Jérôme, Karoui Mehdi, Duvoux Christophe, Dhumeaux Daniel, Fagniez Pierre-Louis
Department of Digestive Surgery, Liver Transplantation and Hepatobiliary Unit, APHP, Hôpital Henri Mondor-Université Paris 12, Créteil, France.
Ann Surg. 2006 Apr;243(4):499-506. doi: 10.1097/01.sla.0000206017.29651.99.
Report the midterm results of laparoscopic resection for hepatocellular in chronic liver disease (CLD).
Surgical resection for hepatocellular carcinoma (HCC) in chronic liver disease (CLD) remains controversial because of high morbidity and recurrence rates. Laparoscopic resection of liver tumors has recently been developed and could reduce morbidity.
From 1998 to 2003, patients with HCC and CLD were considered for laparoscopic liver resection. Inclusion criteria were chronic hepatitis or Child's A cirrhosis, solitary tumor < or =5 cm in size, and location in peripheral segments of the liver. Mortality, morbidity, recurrence rates, and survival were analyzed.
A total of 27 patients were included. Liver resections included anatomic resection in 17 cases and non anatomic resection in 10. Seven conversions to laparotomy (26%) occurred for moderate hemorrhage in 5 cases and technical difficulties in 2 cases. Mortality and morbidity rates were 0% and 33%, respectively. Postoperative ascites and encephalopathy occurred in 2 patients (7%) who both had undergone conversion to laparotomy. Mean surgical margin was 11 mm (range, 1-47 mm). After a mean follow-up of 2 years (range, 1.1-4.7), 8 patients (30%) developed intrahepatic tumor recurrence of which one died. Treatment of recurrence was possible in 4 patients (50%), including orthotopic liver transplantation, right hepatectomy, radiofrequency ablation, and chemoembolization in 1 case each. There were no adhesions in the 2 reoperated patients. Overall and disease-free 3-year survival rates were 93% and 64%, respectively.
Our study shows that laparoscopic liver resection for HCC in selected patients is a safe procedure with very good midterm results. This approach could have an impact on the therapeutic strategy of HCC complicating CLD as a treatment with curative intent or as a bridge to liver transplantation.
报告慢性肝病(CLD)患者肝细胞癌腹腔镜切除术的中期结果。
由于高发病率和复发率,慢性肝病(CLD)患者肝细胞癌(HCC)的手术切除仍存在争议。近年来开展的腹腔镜肝肿瘤切除术可降低发病率。
1998年至2003年,对HCC合并CLD患者进行腹腔镜肝切除术评估。纳入标准为慢性肝炎或Child A级肝硬化、单个肿瘤大小≤5 cm且位于肝外周段。分析死亡率、发病率、复发率和生存率。
共纳入27例患者。肝切除包括17例解剖性切除和10例非解剖性切除。7例(26%)中转开腹,其中5例因中度出血,2例因技术困难。死亡率和发病率分别为0%和33%。2例(7%)术后出现腹水和肝性脑病,均为中转开腹患者。平均手术切缘为11 mm(范围1 - 47 mm)。平均随访2年(范围1.1 - 4.7年)后,8例(30%)出现肝内肿瘤复发,其中1例死亡。4例(50%)复发患者可行治疗,包括原位肝移植、右肝切除术、射频消融和化疗栓塞各1例。2例再次手术患者均无粘连。3年总生存率和无病生存率分别为93%和64%。
我们的研究表明,对选定患者行腹腔镜肝切除治疗HCC是一种安全的手术,中期结果良好。这种方法可能会影响HCC合并CLD的治疗策略,可作为根治性治疗或肝移植的桥梁。